NIKKEI 225
40,573.17 +498.48 (+1.24%) HANG SENG
17,943.56 +174.42 (+0.98%) CRUDE OIL
83.18 +0.37 (+0.45%) GOLD FUTURES
2,342.80 +9.40 (+0.40%) DOW
39,331.85 +162.33 (+0.41%) Bitcoin GBP
47,989.97 -1,658.02 (-3.34%)
KYTX Jul 2024 12.500 call
| Previous close | 0.5000 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 12.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.2000 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireKyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its autologous, fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of stiff-person syndrome (SPS) in Kyverna's trial,
- PR Newswire
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the publication in Proceedings of the National Academy of Sciences (PNAS)1 of a report describing the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS) as p
- PR Newswire
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled "Chimeric antigen receptor T cell therapy for autoimmune disease"1.
